PMID: 9174191Jun 1, 1997Paper

Disposition of atovaquone in humans

Antimicrobial Agents and Chemotherapy
P E RolanJ Posner

Abstract

Atovaquone is an antiprotozoal compound with good in vitro stability against metabolic inactivation. Previous human studies which did not involve radiolabelling had not accounted for a substantial proportion of the dose. The possible metabolism of atovaquone in men was examined in a radiolabelling study involving four healthy male volunteers. Radioactivity was eliminated almost exclusively via the feces. All radioactivity in plasma, urine, and feces was accounted for by atovaquone, with no evidence of metabolites. Radiolabelled atovaquone was administered to a patient with an indwelling biliary tube after surgery. Biliary radioactivity was approximately 10- to 40-fold higher than that in plasma and was accounted for by atovaquone. Atovaquone is not significantly metabolized in humans but is excreted into bile against a high concentration gradient.

References

Jul 1, 1991·The Journal of Infectious Diseases·J Huskinson-MarkJ S Remington
Jan 1, 1994·British Journal of Clinical Pharmacology·P E RolanJ Posner

❮ Previous
Next ❯

Citations

Feb 2, 2013·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Sabine AmetGilbert Deray
Sep 1, 2012·Medical Science Monitor : International Medical Journal of Experimental and Clinical Research·Helieh S Oz, Thomas Tobin
Jan 8, 2013·The Journal of Antimicrobial Chemotherapy·Gemma L NixonGiancarlo A Biagini
Mar 9, 2012·Clinical Pharmacology and Therapeutics·M CellaO Della Pasqua
May 27, 2011·Pharmaceutical Development and Technology·Eleri WallaceCharles M Heard
Aug 9, 2015·European Journal of Drug Metabolism and Pharmacokinetics·Eliane de Oliveira SilvaNiege Araçari Jacometti Cardoso Furtado
Jul 28, 2016·Nature Communications·Thomas M AshtonWilliam Gillies McKenna
Apr 15, 2018·The Journal of Pharmacology and Experimental Therapeutics·Mitesh PatelMaciej J Zamek-Gliszczynski
Apr 18, 2002·Antimicrobial Agents and Chemotherapy·Aaron L Baggish, David R Hill
Sep 15, 2014·Malaria Journal·Sanna R RijpmaJan B Koenderink
Nov 21, 2009·The Lancet Infectious Diseases·Reinhold KerbMatthias Schwab

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.